TriSalus Life Sciences Swaps Board Members

Got story updates? Submit your updates here. ›

TriSalus Life Sciences Inc. (Nasdaq: TLSI), a Westminster-based oncology company, has announced that Arjun Desai has stepped down from the board of directors and is being replaced by Michael Stansky. Stansky brings 40 years of investment management and healthcare experience, having served on the boards of numerous public and private healthcare companies.

Why it matters

Board member changes can signal strategic shifts or new priorities for a company, especially in the healthcare and life sciences sectors. TriSalus is focused on developing technologies to treat hard-to-reach liver and pancreatic tumors, an area of significant unmet medical need.

The details

Michael Stansky most recently served as a Managing Director at Tudor Investment Corporation, where he helped form the firm's equity investment group and was responsible for long/short equity, crossover, and venture investments. Prior to Tudor, Stansky was an analyst and portfolio manager at Wellington Management Company. Stansky currently serves on the boards of Insightec Ltd. and Momentis Surgical, and his past board positions include Mako Surgical Corp., OrthoSensor Inc. and Transmedics Inc.

• Arjun Desai has stepped down from the TriSalus Life Sciences board of directors.